Busiwire
India Pharmaceuticals and Healthcare Report Q3 2008
Tuesday July 22, 10:31 PM
Research and Markets (http://www.researchandmarkets.com/research/70a734/india_pharmaceutic) has announced the addition of the "India Pharmaceuticals and Healthcare Report Q3 2008" report to their offering.
This report provides independent forecasts and competitive intelligence on India's pharmaceuticals and healthcare industry.
Multinationals continue to exhibit their interest in the market. For example, Israeli generic giant Teva is planning to use India for active pharmaceutical ingredient (API) production, with the announcement that it is looking out for acquisitions in the country and setting aside money to expand its own independent manufacturing locally. Similarly, in February 2008, German healthcare company B Braun established a new manufacturing plant in India, while also starting to market a new product range and beginning to seek local collaborators. Additionally, in May 2008, US-based Merck & Co contracted India's Ranbaxy Laboratories to conduct early-stage drug development and clinical research in the antiinfective field, while German healthcare firm Fresenius Kabi recently acquired Dabur India's pharmaceutical division.
On the domestic front, local producers continue to show strength. In April 2008, India's Venus Remedies received accreditation from the General Foreign Trade Organisation (GFTO) of Syria. Venus' move into pharmaceutical markets would be traditionally viewed as risky by Western multinationals, but it demonstrates a key strength of emerging Asian pharmaceutical industries, which are less affected by political baggage. The development shortly follows the creation of Indian drugmaker Glenmark Pharmaceuticals' Romanian subsidiary, as the company aims to increase its presence in the Central and Eastern Europe (CEE) market.
In the meantime, regulatory conditions are expected to improve, with India in the process of replacing its Central Drug Standard Control Organisation (CDSCO) by the Central Drugs Authority of India (CDAI), which will centralise some procedures from individual states, allowing significant efficiencies to be realised. The transformation cannot come a moment too soon, given that the World Health Organization (WHO) criticized India's pharmaceutical regulatory system as recently as April 2008. Nevertheless, the country continues to grow from strength to strength as a location for clinical trials, with the study conducted by the Planning Commission recently revealing that India has now overtaken China as the premier destination for clinical research in Asia.
Key Topics Covered:
-Executive Summary
-India Pharmaceutical Industry SWOT
-India's Pharmaceutical Business Environment Ratings
-Pricing And Reimbursement
-Company Developments
-Industry Forecast Scenario
Companies Mentioned:
-Pfizer
-GlaxoSmithKline (GSK)
-Novartis
-Sanofi-Aventis
-Merck & Co
-Eili Lilly
-Leading Indigenous Manufacturers
-Ranbaxy Laboratories
-Cipla
-Dr Reddy's Laboratories
-Aurobindo Pharmaceutical
-Venus Remedies
-Granules India
-Nicholas Piramal India
-Zydus Cadila
-Dishman Pharmaceuticals and Chemicals
For more information visit http://www.researchandmarkets.com/research/70a734/india_pharmaceutic
Contact:
Research and Markets Laura Wood, Senior Manager Fax from USA: 646-607-1907 Fax from rest of the world: +353-1-481-1716 press@researchandmarkets.com
Next Article: India: The Emerging Giant: Shedding Light on One of the Most Successful Experiments in Economic Development in Modern History
Previous article: Wavion Partners With Three Indian Distributors and Opens a Local Office in India
Top Headlines
Mr Chips offer passes 90 percent threshold
Tuesday September 2, 04:42 PM - NZPA
A takeover offer for potato chip maker Mr Chips Holdings Ltd has passed the 90 percent threshold, achieving acceptances for 9 .. Read More
Higher valuations boost Rural Equities' annual profit
Tuesday September 2, 04:21 PM - NZPA
Rural property investor Rural Equities Ltd saw annual net profit jump to a record high $32. .. Read More
Income receivers for Henderson properties step down
Tuesday September 2, 04:21 PM - NZPA
Receivers appointed for the income of two properties controlled by Christchurch developer Dave Henderson have stepped down af .. Read More
Calculators
Copyright © 2008 Yahoo! All rights reserved.
Yahoo!Xtra: A Yahoo!7/Telecom New Zealand Company.